Co-prescribing of Central Nervous System–Active Medications for COPD Patients: Impact on Emergency Room Visits and Hospitalization

Akhil Sood, Yong Fang Kuo, Jordan Westra, Gulshan Sharma, Mukaila A. Raji

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Anxiety and chronic pain are common comorbidities in patients with chronic obstructive pulmonary disease (COPD), which are frequently managed with benzodiazepines (BZDs) and opioids, respectively. Objective: The purpose of this study was to determine whether different combinations of opioids, BZD, and their substitutes—gabapentinoids (GABA) and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (SSRIs/SNRIs)—are associated with lower risk of acute respiratory events in COPD patients with co-occurring chronic pain and anxiety. Methods: This retrospective cohort study used a nationally representative sample of Medicare beneficiaries with COPD, chronic pain, and anxiety. Patients were grouped based on drug combination (opioid + BZD/Z-hypnotics, opioid + GABA, opioid + SSRI/SNRI, BZD/Z-hypnotics + GABA, BZD/Z-hypnotics + SSRI/SNRI, GABA + SSRI/SNRI, or ≥3 drugs). The primary outcome was emergency room (ER) visit or hospitalization due to acute respiratory events assessed up to 180 days following initiation of drug combination. Overdose secondary to central nervous system (CNS)–related drugs was also assessed up to 180 days following initiation of drug combination. Results: The drug combination opioid + GABA was associated with decreased risk for ER visit (hazard ratio [HR] = 0.73; 95% CI = 0.61-0.87) and hospitalization (HR = 0.69; 95% CI = 0.55-0.85). Opioid + SSRI/SNRI also showed decreased risk for ER visit (HR = 0.84; 95% CI = 0.71-0.99). There was no significant difference in risk for CNS-related drug overdose among different drug combinations compared with opioid + BZD/Z-hypnotics. Conclusion and Relevance: Opioids in combination with GABA and SSRI/SNRI demonstrate relatively lower risk for acute respiratory events among patients with COPD and comorbid chronic pain and anxiety. The findings emphasize the need for multimodal management in this vulnerable population.

Original languageEnglish (US)
Pages (from-to)382-396
Number of pages15
JournalAnnals of Pharmacotherapy
Volume57
Issue number4
DOIs
StatePublished - Apr 2023

Keywords

  • COPD
  • benzodiazepines
  • gabapentinoids
  • opioids
  • selective serotonin reuptake inhibitors
  • serotonin and norepinephrine reuptake inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Co-prescribing of Central Nervous System–Active Medications for COPD Patients: Impact on Emergency Room Visits and Hospitalization'. Together they form a unique fingerprint.

Cite this